- Perspective Therapeutics to Participate at Upcoming May Investor Conferences
- Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results
- Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
- Perspective Therapeutics to Participate at Upcoming April Investor Conferences
- Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
- Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024
- Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility
- Perspective Therapeutics Announces $87.4 Million Private Placement
- Perspective Therapeutics to Participate at Upcoming Investor Conferences
- Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
More ▼
Key statistics
As of last trade Perspective Therapeutics Inc (CATX:ASQ) traded at 1.65, -13.39% below its 52-week high of 1.91, set on May 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.62 |
---|---|
High | 1.65 |
Low | 1.54 |
Bid | 1.64 |
Offer | 1.65 |
Previous close | 1.60 |
Average volume | 8.23m |
---|---|
Shares outstanding | 587.20m |
Free float | 449.70m |
P/E (TTM) | -- |
Market cap | 939.51m USD |
EPS (TTM) | -0.1622 USD |
Data delayed at least 15 minutes, as of May 20 2024 16:28 BST.
More ▼